文献速递新生儿儿童神经与发育行为

新生儿缺氧缺血性脑病脑损伤的血浆生物标志物

Plasma Biomarkers of Brain Injury in Neonatal Hypoxic-Ischemic Encephalopathy.
PubMed 文献 · J Pediatr · 2018-01-01

本研究在评价促红细胞生成素神经保护作用的II期多中心随机试验背景下,分析50名脑病新生儿基线(<24小时)和日龄5天的血浆脑特异性蛋白与细胞因子,发现基线S100B、Tau、UCH-L1及多种细胞因子升高与MRI脑损伤严重程度加重相关,基线Tau较高和日龄5天BDNF较低与1年神经发育结局较差相关。

要点

  • 基线S100B、Tau、UCH-L1及IL-1β、IL-6、IL-8、IL-10、IL-13、TNF-α、IFN-γ升高与MRI脑损伤严重程度加重相关。
  • 基线Tau较高和日龄5天BDNF较低与1年神经发育结局较差相关。
  • 本小样本队列未检测到促红细胞生成素治疗对生物标志物关系的显著修饰证据。

核心结论

  • HIE新生儿生后24小时内血浆脑特异性蛋白和细胞因子升高与MRI评估的脑损伤加重相关。
  • 仅Tau和BDNF水平与神经发育结局相关。
  • 促红细胞生成素治疗对生物标志物与脑损伤关系的影响需进一步研究。

研究设计与样本

  • 在评价促红细胞生成素神经保护作用的II期多中心随机试验背景下开展候选脑损伤生物标志物研究。
  • 纳入50名脑病新生儿,基线(<24小时)和日龄5天采集血浆。
  • 脑损伤通过MRI评估,并在1岁时进行神经发育评估。

主要发现

  • 基线S100B、Tau、UCH-L1、IL-1β、IL-6、IL-8、IL-10、IL-13、TNF-α和IFN-γ水平升高与MRI脑损伤严重程度加重相关。
  • 基线Tau较高和日龄5天BDNF较低与1年结局较差相关。
  • 本小样本队列未检测到促红细胞生成素治疗对生物标志物的显著修饰证据。

临床怎么用

  • 生后24小时内血浆S100B、Tau、UCH-L1及特定细胞因子水平可辅助评估HIE新生儿MRI脑损伤严重程度。
  • 基线Tau和日龄5天BDNF或可辅助预测1年神经发育结局。
  • 促红细胞生成素治疗与生物标志物关系暂不明确,需进一步研究。

局限性

  • 样本量小(50名新生儿),限制统计效能。
  • 未检测到促红细胞生成素治疗对生物标志物的显著修饰证据,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate plasma brain specific proteins and cytokines as biomarkers of brain injury in newborns with hypoxic-ischemic encephalopathy (HIE) and, secondarily, to assess the effect of erythropoietin (Epo) treatment on the relationship between biomarkers and outcomes. STUDY DESIGN: A study of candidate brain injury biomarkers was conducted in the context of a phase II multicenter randomized trial evaluating Epo for neuroprotection in HIE. Plasma was collected at baseline (<24 hours) and on day 5. Brain injury was assessed by magnetic resonance imaging (MRI) and neurodevelopmental assessments at 1 year. The relationships between Epo, brain-specific proteins (S100B, ubiquitin carboxy-terminal hydrolase-L1 [UCH-L1], total Tau, neuron specific enolase), cytokines (interleukin [IL]-1β, IL-6, IL-8, IL-10, IL-12P70, IL-13, interferon-gamma [IFN-γ], tumor necrosis factor alpha [TNF-α], brain-derived neurotrophic factor [BDNF], monocyte chemoattractant protein-1), and brain injury were assessed. RESULTS: In 50 newborns with encephalopathy, elevated baseline S100B, Tau, UCH-L1, IL-1β, IL-6, IL-8, IL-10, IL-13, TNF-α, and IFN-γ levels were associated with increasing brain injury severity by MRI. Higher baseline Tau and lower day 5 BDNF were associated with worse 1 year outcomes. No statistically significant evidence of Epo treatment modification on biomarkers was detected in this small cohort. CONCLUSIONS: Elevated plasma brain-specific proteins and cytokine levels in the first 24 hours of life are associated with worse brain injury by MRI in newborns with HIE. Only Tau and BDNF levels were found to be related to neurodevelopmental outcomes. The effect of Epo treatment on the relationships between biomarkers and brain injury in HIE requires further study. TRIAL REGISTRATION: ClinicalTrials.gov: 01913340.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Massaro AN, Wu YW, Bammler TK, et al. Plasma Biomarkers of Brain Injury in Neonatal Hypoxic-Ischemic Encephalopathy. J Pediatr. 2018. PMID: 29478510. doi:10.1016/j.jpeds.2017.10.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。